Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Zeitschrift Fur Rheumatologie
|
May 25, 2017
[Off-label biological therapies in patients with large vessel vasculitis and/or polymyalgia rheumatica : Safety and efficacy analysis of a nationwide German registry (GRAID2)]
J C Henes, H Schulze-Koops, M Witt, et al.
Molecular Psychiatry
|
April 18, 2012
The ADHD-susceptibility gene lphn3.1 modulates dopaminergic neuron formation and locomotor activity during zebrafish development
M Lange, W Norton, M Coolen, et al.
Molecular Psychiatry
|
August 25, 2012
The ADHD-linked gene Lphn3.1 controls locomotor activity and impulsivity in zebrafish
M Lange, W Norton, M Coolen, et al.
Zeitschrift Fur Rheumatologie
|
May 17, 2017
[Off-label biologic therapy of ANCA-associated and non-ANCA-associated small-vessel vasculitis : Efficacy and safety analysis of a national registry (GRAID2)]
N Venhoff, F Proft, H Schulze-Koops, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology
|
November 22, 2015
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID)
P S Rommer, T Dörner, K Freivogel, et al.
Scandinavian Journal of Rheumatology
|
September 11, 2014
Gustatory and olfactory function in patients with granulomatosis with polyangiitis (Wegener's)
F Proft, S Steinbach, C Dechant, et al.
Translational Psychiatry
|
October 14, 2015
Cadherin-13, a risk gene for ADHD and comorbid disorders, impacts GABAergic function in hippocampus and cognition
O Rivero, M M Selten, S Sich, et al.
Lupus
|
September 24, 2013
Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID)
M Witt, M Grunke, F Proft, et al.
Zeitschrift Fur Rheumatologie
|
June 8, 2017
[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)]
F Proft, H Schulze-Koops, M Grunke, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Zeitschrift Fur Rheumatologie
|
May 25, 2017
[Off-label biological therapies in patients with large vessel vasculitis and/or polymyalgia rheumatica : Safety and efficacy analysis of a nationwide German registry (GRAID2)]
J C Henes, H Schulze-Koops, M Witt, et al.
Molecular Psychiatry
|
April 18, 2012
The ADHD-susceptibility gene lphn3.1 modulates dopaminergic neuron formation and locomotor activity during zebrafish development
M Lange, W Norton, M Coolen, et al.
Molecular Psychiatry
|
August 25, 2012
The ADHD-linked gene Lphn3.1 controls locomotor activity and impulsivity in zebrafish
M Lange, W Norton, M Coolen, et al.
Zeitschrift Fur Rheumatologie
|
May 17, 2017
[Off-label biologic therapy of ANCA-associated and non-ANCA-associated small-vessel vasculitis : Efficacy and safety analysis of a national registry (GRAID2)]
N Venhoff, F Proft, H Schulze-Koops, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology
|
November 22, 2015
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID)
P S Rommer, T Dörner, K Freivogel, et al.
Scandinavian Journal of Rheumatology
|
September 11, 2014
Gustatory and olfactory function in patients with granulomatosis with polyangiitis (Wegener's)
F Proft, S Steinbach, C Dechant, et al.
Translational Psychiatry
|
October 14, 2015
Cadherin-13, a risk gene for ADHD and comorbid disorders, impacts GABAergic function in hippocampus and cognition
O Rivero, M M Selten, S Sich, et al.
Lupus
|
September 24, 2013
Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID)
M Witt, M Grunke, F Proft, et al.
Zeitschrift Fur Rheumatologie
|
June 8, 2017
[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)]
F Proft, H Schulze-Koops, M Grunke, et al.
Page
of 2